Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Drug Discovery & Development » Precision Oncology Highlights From ESMO 2018

Precision Oncology Highlights From ESMO 2018

Oct 30, 2018
|
staff reporter

NEW YORK (GenomeWeb) – The European Society of Medical Oncology's annual meeting in Munich, Germany featured data from studies involving cancer drugs that target molecular aberrations driving patients' tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jun
02
Featured Webinar

The Need for Digital Spatial Profiling for Host-Pathogen Interaction: A York Perspective

Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Jun
04
Featured Webinar

COVID-19 Testing, Treatment and Future Outlook

Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

What's Popular?

In Cancer

  1. Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients

  2. Oncologists Make Progress Toward Showing Utility for Brain Cancer Liquid Biopsy

  3. Pediatric Precision Oncology Study Matches 28 Percent of Patients to Targeted Therapies

  4. Polygenic Risk Score, Family History Refine Breast Cancer Risk Assessment in CHEK2 Mutation Carriers

  5. Oncotype DX May Be Helpful in Guiding Neoadjuvant Breast Cancer Treatment Decisions

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.